Hospital Care

Hospital or Critical care medicine encompasses the diagnosis and treatment of a wide variety of clinical problems representing the extreme of human disease. Critical care usually takes place in an intensive care unit (ICU) of hospitals for people who have life-threatening injuries and/or illnesses. A team of specially trained healthcare providers gives round-the-clock care. This includes using machines to constantly monitor patients’ vital signs. It also usually involves giving specialized treatments. The care of critically ill patients raises many complicated ethical and social issues, and the intensivist must be competent in areas such as end-of-life decisions, advance directives, estimating prognosis, and counseling of patients and their families. Diagnosis of infection by healthcare practitioners plays an important role in timely treatment. Nosocomial infections are key concern for such critically ill patients.1,2

We offer a range of medicines to fight all kinds of infections, be it bacterial or fungal. We make anti-infectives available and accessible to all. We partner with the healthcare professionals to spread awareness about emerging threats, latest guidelines, diagnosis, options, and strategies for treatment of critical patients.1,2

Product portfolio

  • Ambisome® (Liposomal Amphotericin B 50 mg)
  • Posatral® IV (Posaconazole 300 mg)
  • Posatral® Tablets (Posaconazole 100 mg)
  • AnidulanTM (Anidulafungin 100 mg)
  • Micalan® (Micafungin 50 mg)
  • MerowinTM 1 g (Meropenem 1000 mg)
  • MerowinTM 500 mg (Meropenem 500 mg)
  • ImilanTM (Imipenem & Cilastatin 500 mg)
  • TygarayTM (Tigecycline 50 mg)
  • Telanin® (Teicoplanin 400 mg)
  • Ceflen® 1.5 g (Cefoperazone & Sulbactam 1.5 g)
  • Ceflen® 3 g (Cefoperazone & Sulbactam 3 g)
  • Viacease-B® (Polymyxin B 500000IU)

1. https://medlineplus.gov/criticalcare.html
2. https://www.acponline.org/about-acp/about-internal-medicine/subspecialties-of-internal-medicine/critical-care-medicine

Non-communicable Diseases

Non-communicable diseases (NCDs) are medical conditions that are not caused by infectious agents, generally they are slow in progression and chronic in nature. The incidence of these ailments is due to various factors viz. genetic, physiological, environmental & lifestyle changes.1

Our product offerings provide treatment options for conditions like Neuropathic Pain, OA (Osteo Arthritis) RA (Rheumatoid Arthritis), Acute Pain Management, Depression, Men’s Health, Hypertension, Epilepsy and Glaucoma.

  • Lyrica® (Pregabalin 75 mg, 100 mg capsules)
  • Celebrex® (Celecoxib 100 mg, 200 mg capsules)
  • Daxid® (Sertraline 25 mg, 50 mg, 100 mg tablets)
  • Viagra® (Sildenafil Citrate, 50 mg, 100 mg tablets)
  • Xalatan® (Latanoprost, mcg/ml, eye drops)
  • XalacomTM (Latanoprost & Timolol Maleate Combination. mcg/ml, eye drops)
  • Amlogard® (Amlodipine 2.5 mg, 5 mg, 10 mg tablets)
  • Dilantin® (Phenytoin/Phenytoin Sodium 100 mg Kapseals, Suspension 100 mg bottle, 2 ml injection)

1. Non-communicable Diseases | National Health Portal Of India

Oncology

We offer one of the industry’s most diverse global franchises focused on Oncology. Our strong array of Oncology products reflects our commitment to increasing patient access to quality, affordable medicines in India.

The brands Dasamyl, Lenris and Lentris for treatment of CML and HCC, RCC and DTC respectively, flags off the new launches & will remain to be priority brands in future.

Ashray – Patient Assistance Program, our patient care system is one of its kind in the industry and extends beyond access to quality medicines, continues to be pivotal to our access mission catering to over 500 more patients YTD & a program which has benefitted 3,000+ patients.

Our robust portfolio of therapeutic, supportive care & diagnostic products forms the backbone of Oncology care.

  • Viatris: Global Healthcare Company. Available at: https://www.viatris.com/en. Accessed on: 22 February 2022.
  • Dermacare product portfolio. Data on file.

Public Health Business

i. COVID Therapy

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with the virus experience mild to moderate respiratory illness and recover without requiring special treatment. However, some become seriously ill and require medical attention. Older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness.

Globally, as of 22 April 2022, there have been 505,817,953 confirmed cases of COVID-19, including 6,213,876 deaths, reported to WHO.1

In India, as of 25th April 2022, there have been 43,060,086 confirmed cases and 42,521,341 recovered cases.2

Viatris offers the following products for the treatment of COVID-19:

1. DESREM® – (Remdesivir 100 mg/vial Lyophilized Powder for Injection for IV Infusion)
2. FAVTRIS® – (Favipiravir 800 mg/ 400 mg/ 200 mg) tablets
3. MOLNATRIS® – (Molnupiravir 200 mg) capsules

1. WHO: Coronavirus
2. Data from: CDC · WHO · ECDC dashboard


ii. Digital Therapeutics

Digital therapeutics is a new field that involves using data collected from electronic health records (e-health) to treat patients as opposed to just drug testing. Software or devices are used to take health data and then they take steps to cure them. This trend is interesting for patients who don’t have access to conventional doctors but suffer from chronic diseases.1

Artificial intelligence (AI) and machine learning are all about data and information, training specialized programs with the data like patient's history, lab test results, scan results, and symptoms data can result in an efficient and more accurate information regarding diseases.2 With advanced scanning technologies and information management approaches, the future of AI in healthcare seems brighter than before.

1. Future of Digital Therapeutics Industry in India.
2. Artificial Intelligence (AI) for Disease Diagnosis


iii. Anti-Tubercular Therapy

The treatment of tuberculosis (TB) presents an enormous challenge to global health. Tuberculosis is a leading cause of death from infectious diseases worldwide. Although several therapeutics and vaccines are available to treat and prevent tuberculosis infections, more virulent varieties of tuberculosis and increased drug resistance in the form of multi, extreme, and total drug resistant disease are major emergent threats. It is essential that therapeutic and research strategies targeted at tuberculosis should reflect this co-evolution.1

A total of 1.5 million people died from TB in 2020 (including 214 000 people with HIV). Worldwide, TB is the 13th leading cause of death and the second leading infectious killer after COVID 19. Globally, TB incidence is falling at about 2% per year and between 2015 and 2020 the cumulative reduction was 11%. This was over halfway to the End TB Strategy milestone of 20% reduction between 2015 and 2020.2

Viatris provides DELTYBA (Delamanid 50 mg) tablets for the treatment of multidrug-resistant tuberculosis (MDR-TB). Delamanid must always be administered as part of an appropriate combination regimen for the treatment of MDR-TB. Treatment with an appropriate combination regimen should continue after the completion of the 24-week delamanid treatment period according to WHO guidelines. It is recommended that delamanid is administered by directly observed therapy (DOT).

1. Ellis, SDP., & Carthy, E. R. (2013). Book Review: The New Paradigm of Immunity to Tuberculosis. Frontiers in Immunology, 4, 386. https://doi.org/10.3389/fimmu.2013.00386
2. WHO: Tuberculosis

Virology

i. Antiretroviral Therapy for HIV

Through our predecessor companies, Viatris has been on the frontlines of the global fight against human immunodeficiency virus (HIV) for more than a decade and will continue to lead and build partnerships to ensure access to the tools that combat this disease.1

Viatris is the world's largest supplier of antiretrovirals (ARVs) by volume, in low- and lower-middle–income countries. Our products treat five times more people living with HIV per day than all the branded originators combined.1

Our commitment to alleviating the disease burden of HIV is grounded in three pillars:

  • Access:
    • For a decade, Viatris has helped expand access by making new HIV medications available and affordable.
  • Leadership:
    • We have been at the forefront of the first-line HIV treatment regimen for adults new to ARV treatment and are also addressing the unique challenge of treating infants and children living with HIV.
  • Partnership:
    • Viatris is expanding its reach to build healthier, more sustainable communities through partnerships. We are collaborating with organisations, such as the Bill & Melinda Gates Foundation, to develop a product that combines HIV prevention and contraception.

Apart from these central pillars, we are also dedicated to:

  • Addressing other conditions affecting people living with HIV
  • Working with a variety of organisations to support free community testing and awareness campaigns
  • Ensuring sufficient supply of our HIV medications

Everyone, no matter where they live, should have access to HIV treatment. That is the future we envision. Because at Viatris, we see healthcare not as it is, but as it should be.

ARV: Antiretrovirals; HIV: Human immunodeficiency virus.

Comprehensive Range of Antiretrovirals

Viatris offers a comprehensive range of antiretroviral tablets of various doses as seen below.

  • Teevir® - (Emtricitabine 200 mg +Tenofovir disoproxil fumarate 300 mg+ Efavirenz 600mg) tablets
  • Efamat® - (Efavirenz (600 mg) tablets
  • Telura® - (Tenofovir disoproxil fumarate 300 mg + Lamivudine 300 mg + Efavirenz 600 mg) tablets
  • Alltera® - (Lopinavir 200 mg + Ritonavir 50 mg) tablets
  • Anzavir R® - (Atazanavir 300 mg + Ritonavir 100 mg) tablets
  • Zovilam® 60T - (Zidovudine 150 mg + Lamivudine 300 mg) tablets
  • Ricovir EM® - (Tenofovir DF 300 mg + Emtricitabine 200 mg) tablets
  • Avonza® - (Tenofovir DF 300 mg + Lamivudine 300 mg + Efavirenz 400 mg) tablets
  • Albavir® - (Abacavir Sulphate 600 mg + Lamivudine 300 mg) tablets
  • Durart-R® 450 - (Darunavir 400 mg + Ritonavir 50 mg) tablets
  • Taficita® - (Tenofovir AF 25 mg + Emtricitabine 200 mg) tablets
  • Myltega® - (Dolutegravir Sulphate 50 mg) tablets

1. Viatris Newsroom. Viatris’ Commitment to the HIV/AIDS Community. Available at: https://newsroom.viatris.com/Viatris-Commitment-to-the-HIV-AIDS-Community. Accessed on: 24 April 2022.


ii. Dermatology: Right to Healthy Skin with Accessible High-Quality Skincare Products

Viatris in collaboration with strategic partners and sales and marketing efforts helps patient to access superior medicines for skin health.1 The Viatris India Dermatology division strives to empower individuals and provide healthy skin for all. It has a wide range of skincare products targeting non-infectious and infectious skin diseases and provides skin protection.2
Our products cater to patients for treatment of2

  • Atopic dermatitis:
    • Elidel® (Pimecrolimus) Cream
    • MyLimus™ (Tacrolimus) Ointment
    • Desoint® (Desonide) Cream
  • Fungal skin infection:
    • Amtris® (Amorolfine-Phenoxyethanol) Cream
    • Leubine® (Luliconazole) Cream
  • Psoriasis:
    • MPrila™ (Apremilast) Tablet

Our other skincare products include Sunscreen (Suntris®), Emollient (CIDEAD®), and Facewashes (Cleale® and Brillinz®).

  1. Viatris: Global Healthcare Company. Available at: https://www.viatris.com/en. Accessed on: 22 February 2022.
  2. Dermacare product portfolio. Data on file.

iii. Dermocosmetic

Viatris is committed to developing holistic solutions for the prevention and treatment of health conditions. Viatris produces high-quality products and strives to improve access to medication.1 Viatris India in collaboration with Ivatherm (a Romania based dermocosmetic company) provides customers with a complete range of dermocosmetics for treatment and daily skincare through its new business entity.1,2

  • Ivapur for mixed, oily or oil-prone skin
    • Purifying Cleansing Gel
    • Ivapur A.I. Akne-Syt Cream
    • Ivapur K Cream
  • Ivahidra+ for dry to very dry atopic skin
    • Emollient Body Cream
    • Emollient Cleansing Gel
  • IvaWhite for melasma or hyperpigmentation pathologies
    • Intensive Whitening Serum
    • Whitening Cream
  • Herculane thermal water for calming and soothing sensitive skin
  • Sunlight for intense sun protection for all sensitive skin types
    • Dry Touch
  1. Viatris: Global Healthcare Company. Available at https://www.viatris.com/en. Accessed on 22 February 2022.
  2. Ivatherm product portfolio. Data on file.

iv. Gastroenterology

The gut is often referred to as the body’s second brain. The digestive system provides energy and fuel for the whole body, so when someone suffers from gastrointestinal disorders, their life can be put on hold. Gastrointestinal disorders refer to diseases involving the gastrointestinal tract, namely the oesophagus, stomach, small intestine, large intestine and rectum, and the accessory organs of digestion, the liver, gallbladder, and pancreas.

Viatris, being the leader in the Chronic hepatitis treatment market**, has now expanded its presence in different segments and specialties with a vision to lead that market. We have a dedicated team that promotes and drives the visibility and access of our gastroportfolio to various specialties of doctors and other stakeholders.

We offer a broad range of digestive solutions catering to heartburn, constipation, diarrhea, biliary disorders, liver health, gut microbiome etc. The portfolio offers accessible products like Pantoprazol, Pantoprazol + Domperidone, Pantoprazol + Levosulpiride, which works on relieving acidity, indigestion, heartburn, and peptic ulcers. Prucalopride is a new-age solution for an age-old disorder for the management of chronic idiopathic constipation. Other therapeutic drugs include Ursodeoxycholic acid, Obeticholic acid, Probiotics, Digestive enzymes, Antibiotics for managing bacterial infections and various other nutraceutical range.

With the increase in unhealthy eating habits & sedentary lifestyles, gastric disorders are expected to rise further in the coming years. Viatris is all geared up to touch base the lives of millions with a robust gastric drug pipeline in place, thereby improving the patient outcomes via access to the medication and empowering people to live healthier at every stage of life.

We provide a wide portfolio of medicines for indications as below.

  • Primary Biliary Cholangitis
    • Ursobiac® 300 (Ursodeoxycholic Tab 300 mg)
  • Chronic Constipatiom
    • Prugonist® 1 (Prucalopride Tab 1 mg)
    • Prugonist® 2 (Prucalopride Tab 2 mg)
  • Primary Biliary Cholangitis
    • Eticholic® 5 (Obeticholic Acid 5 mg)
    • Eticholic® 10 (Obeticholic Acid 10 mg)
  • Respiratory Tract Infection
    • Penlactic® 375 (Amoxicillin 250 mg + Clavulanic Acid 125 mg)
  • Bacterial Lower Respiratory Tract Infection
    • Penlactic® 625 (Amoxicillin 500 mg + Clavulanic Acid 125 mg)
    • Penlactic® 1000 (Amoxicillin 875 mg + Clavulanic Acid 125 mg)
  • Gastroesophageal Reflux Disease
    • MyPrazol® (Pantoprazole 40 mg)
    • MyPrazol® D (Pantoprazole 40 mg + Domperidone 10 mg)
    • MyPrazol® L (Pantoprazole 40 mg + Levosulpiride 75 mg)
    • MyPrazol® INJ (Pantoprazole 40 mg Injection)
  • Diabetic Neuropathy
    • Myfocoly® (Alphalipoic Acid 100 mcg + Pyridoxine Hcl 3 mg + Mrthyl Cobalamine 1500 mcg + Folic Acid 1.5 mg)
  • Allergic Rhinitis
    • Mytecit® L (Montelukast 10 mg + Levocetirizine 5 mg)
    • Mytecit® F (Montelukast 10 mg + Fexofenadine 120 mg)

** Data on File – HBV and HCV: Moving Annual Total. IMS Health. December 2021


v. Hepatitis

Hepatitis is a virus-induced liver infection. It is an asymptomatic disease and in chronic cases leads to severe damage to the liver, if not treated. India has a population of 1.3 billion and carries a global burden of 10% - 12% for hepatitis*.

Viatris, being the leader in the Chronic hepatitis treatment market**, has always played a key role in driving the commitment to make India a hepatitis-free nation.

Viatris offers access to the complete range of Hepatitis B and Hepatitis C drugs. The portfolio comprises of Tenofovir Alafenamide (TAF), Tenofovir Disoproxil Fumarate (TDF) and Entecavir (ETV) for the management of Chronic Hepatitis B infected patients and Sofosbuvir + Velpatasvir, Sofosbuvir + Daclatasvir, Sofosbuvir + Ledipasvir, Sofosbuvir, and Daclatasvir for the treatment of all genotypes of Chronic Hepatitis C infected patients.

Over the years our role has been crucial in creating awareness about Hepatitis among the masses via awareness lectures, street plays, awareness rallies, etc.

Hepbeat.com, a digital platform was introduced in 2021 to reach out to a diverse population and build awareness in prominent regional languages of India. We have been providing aid to hepatitis-infected patients via our patient support programs – Screening, Diagnostic, and Counselling by leveraging our strong connections and partnerships with the experts and health service providers in India.

Viatris continues to empower hepatitis-infected patients to live healthier lives in India with a 360⁰ ecosystem in hepatitis management.

Viatris offers several products for the treatment of Chronic Hepatitis B & C.

  • Chronic Hepatitis B:
    • Ricovir® (Tenofovir Disoproxil Fumarate 300 mg)
    • HepBest® (Tenofovir Alafenamide Fumerate – 25 mg)
    • Gepatit® 0.5 mg (Entecavir 0.5 mg)
  • Chronic Hepatitis C:
    • MyDekla® 60 mg (Daclatasvir 60 mg)
    • MyHep® (Sofosbuvir 400 mg)
    • MyHep DVIR® (Daclatasvir 60 mg and Sofosbuvir 400 mg)
    • MyHep LVIR® (Ledipasvir and Sofosbuvir 90/400 mg)
    • MyHep ALL® (Sofosbuvir 400mg/Velpatasvir 100 mg)

* Govt. of India. Viral Hepatitis – The silent disease Facts and Treatment Guidelines. https://ncdc.gov.in/linkimages/guideline_hep20158117187417.pdf ** Data on File – HBV and HCV: Moving Annual Total. IMS Health. December 2021


vi. Immunosuppressant

Solid organ transplantations save lives in patients affected by terminal organ failures and improve quality of life. Preventing organ rejection and fighting infection is a delicate balance that requires close attention and care for the rest of life. We at Viatris plant hope and life in millions of patients with our comprehensive range of immunosuppressants that are used in optimum dosage to maintain this crucial balance.

Viatris’ immunosuppressant portfolio includes Tacrolimus, Mycophenolate mofetil, Mycophenolic acid, and Everolimus. We have a dedicated team of people who drives the access and affordability of our immunosuppressant portfolio to nephrologists, hepatologists and transplant surgeons across the country.

Our patient care system is one of its kind in the industry and extends beyond access to quality medicines. It also comprises of various awareness, diagnostics and counseling support to make the patients live life minus the fear of graft failure.

Product portfolio

  • MyLimus® 0.5 (Tacrolimus Cap 0.5 mg)
  • MyLimus® 1 (Tacrolimus Cap 1 mg)
  • Mylimus® 2 (Tacrolimus 2 mg)
  • Graftide-S® 360 (Mycophenolate Sodium 360 mg)
  • Graftide-M® 500 (Mycophenolate Mofetil 500 mg)
  • Lanolimus® 0.25 (Everolimus Tab 0.25 mg)
  • Lanolimus® 0.5 (Everolimus Tab 0.5 mg)